BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 33176935)

  • 1. Enhanced post-licensure safety surveillance of a new recombinant acellular pertussis vaccine licensed as a monovalent (aP, Pertagen®) and tetanus, reduced-dose diphtheria combination (TdaP, Boostagen®) vaccine for immunization of adolescents and adults in Thailand.
    Fortuna L; Chaithongwongwatthana S; Soonthornworasiri N; Spiegel J; Wijagkanalan W; Mansouri S; van den Biggelaar AHJ; Pham HT
    Vaccine; 2020 Dec; 38(51):8194-8199. PubMed ID: 33176935
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A genetically inactivated two-component acellular pertussis vaccine, alone or combined with tetanus and reduced-dose diphtheria vaccines, in adolescents: a phase 2/3, randomised controlled non-inferiority trial.
    Sricharoenchai S; Sirivichayakul C; Chokephaibulkit K; Pitisuttithum P; Dhitavat J; Pitisuthitham A; Phongsamart W; Boonnak K; Lapphra K; Sabmee Y; Wittawatmongkol O; Chinwangso P; Poredi IK; Petre J; Thai PH; Viviani S
    Lancet Infect Dis; 2018 Jan; 18(1):58-67. PubMed ID: 29066131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and immunogenicity of a combined Tetanus, Diphtheria, recombinant acellular Pertussis vaccine (TdaP) in healthy Thai adults.
    Sirivichayakul C; Chanthavanich P; Limkittikul K; Siegrist CA; Wijagkanalan W; Chinwangso P; Petre J; Hong Thai P; Chauhan M; Viviani S
    Hum Vaccin Immunother; 2017 Jan; 13(1):136-143. PubMed ID: 27686283
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase 2 randomized controlled dose-ranging trial of recombinant pertussis booster vaccines containing genetically inactivated pertussis toxin in women of childbearing age.
    Chokephaibulkit K; Puthanakit T; Bhat N; Mansouri S; Tang Y; Lapphra K; Rungmaitree S; Anugulruengkitt S; Jantarabenjakul W; Andi-Lolo I; Holt R; Fortuna L; Kerdsomboon C; Chinwangso P; Suwitruengrit L; van den Biggelaar AHJ; Viviani S; Pham HT; Innis BL
    Vaccine; 2022 Apr; 40(15):2352-2361. PubMed ID: 34789403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase 2 randomized controlled dose-ranging trial of recombinant pertussis booster vaccines containing genetically inactivated pertussis toxin in pregnant women.
    Puthanakit T; Chokephaibulkit K; Chaithongwongwatthana S; Bhat N; Tang Y; Anugulruengkitt S; Chayachinda C; Anuwutnavin S; Lapphra K; Rungmaitree S; Tawan M; Andi-Lolo I; Holt R; Fortuna L; Kerdsomboon C; Yuwaree V; Mansouri S; Thai PH; Innis BL
    Vaccine; 2023 Jul; 41(31):4541-4553. PubMed ID: 37330371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomised, double-blind, non-inferiority clinical trial on the safety and immunogenicity of a tetanus, diphtheria and monocomponent acellular pertussis (TdaP) vaccine in comparison to a tetanus and diphtheria (Td) vaccine when given as booster vaccinations to healthy adults.
    Thierry-Carstensen B; Jordan K; Uhlving HH; Dalby T; Sørensen C; Jensen AM; Heilmann C
    Vaccine; 2012 Aug; 30(37):5464-71. PubMed ID: 22776216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantity and Quality of Antibodies After Acellular Versus Whole-cell Pertussis Vaccines in Infants Born to Mothers Who Received Tetanus, Diphtheria, and Acellular Pertussis Vaccine During Pregnancy: A Randomized Trial.
    Wanlapakorn N; Maertens K; Vongpunsawad S; Puenpa J; Tran TMP; Hens N; Van Damme P; Thiriard A; Raze D; Locht C; Poovorawan Y; Leuridan E
    Clin Infect Dis; 2020 Jun; 71(1):72-80. PubMed ID: 31418814
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Levels of antibodies specific to diphtheria toxoid, tetanus toxoid, and Haemophilus influenzae type b in healthy children born to Tdap-vaccinated mothers.
    Wanlapakorn N; Maertens K; Thongmee T; Srimuan D; Thatsanathorn T; Van Damme P; Leuridan E; Poovorawan Y
    Vaccine; 2020 Oct; 38(44):6914-6921. PubMed ID: 32888740
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Broder KR; Cortese MM; Iskander JK; Kretsinger K; Slade BA; Brown KH; Mijalski CM; Tiwari T; Weston EJ; Cohn AC; Srivastava PU; Moran JS; Schwartz B; Murphy TV;
    MMWR Recomm Rep; 2006 Mar; 55(RR-3):1-34. PubMed ID: 16557217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention of pertussis, tetanus, and diphtheria among pregnant and postpartum women and their infants recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Murphy TV; Slade BA; Broder KR; Kretsinger K; Tiwari T; Joyce PM; Iskander JK; Brown K; Moran JS;
    MMWR Recomm Rep; 2008 May; 57(RR-4):1-51. PubMed ID: 18509304
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effective and safe transfer of maternal antibodies persisting two months postpartum following maternal immunization with different doses of recombinant pertussis-containing vaccines.
    Chokephaibulkit K; Puthanakit T; Chaithongwongwatthana S; Bhat N; Tang Y; Anugulruengkitt S; Chayachinda C; Anuwutnavin S; Lapphra K; Rungmaitree S; Tawan M; Andi-Lolo I; Holt R; Fortuna L; Kerdsomboon C; Yuwaree V; Mansouri S; Thai PH; Innis BL
    Vaccine; 2024 Jan; 42(2):383-395. PubMed ID: 38061956
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spotlight on Tdap₅ vaccine (Covaxis®) as a single-booster immunization for the prevention of tetanus, diphtheria, and pertussis: in children (aged ≥4 years), adolescents, and adults.
    Scott LJ
    Paediatr Drugs; 2011 Apr; 13(2):133-5. PubMed ID: 21351814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity and safety of a second booster dose of an acellular pertussis vaccine combined with reduced antigen content diphtheria-tetanus toxoids 10 years after a first booster in adolescence: An open, phase III, non-randomized, multi-center study.
    Kovac M; Kostanyan L; Mesaros N; Kuriyakose S; Varman M
    Hum Vaccin Immunother; 2018; 14(8):1977-1986. PubMed ID: 29630439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention of pertussis among adolescents: recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine.
    America Academy of Pediatrics Commitee on Infectious Diseases
    Pediatrics; 2006 Mar; 117(3):965-78. PubMed ID: 16382131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety of reduced-antigen-content tetanus-diphtheria-acellular pertussis vaccine in adolescents as a sixth consecutive dose of acellular pertussis-containing vaccine.
    Zepp F; Knuf M; Habermehl P; Mannhardt-Laakmann W; Howe B; Friedland LR
    J Pediatr; 2006 Nov; 149(5):603-610. PubMed ID: 17095328
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity and safety of reduced-antigen tetanus, diphtheria and acellular pertussis vaccination in adults treated for obstructive airway diseases.
    Van den Steen P; Cheuvart B; Deraedt Q; Valdes Verelst L; Shamarina D
    Hum Vaccin Immunother; 2023 Dec; 19(1):2159731. PubMed ID: 36746754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody persistence 2 and 3 years after booster vaccination of adolescents with recombinant acellular pertussis monovalent aP
    Pitisuttithum P; Dhitavat J; Sirivichayakul C; Pitisuthitham A; Sabmee Y; Chinwangso P; Kerdsomboon C; Fortuna L; Spiegel J; Chauhan M; Poredi IK; van den Biggelaar AHJ; Wijagkanalan W; Viviani S; Mansouri S; Pham HT
    EClinicalMedicine; 2021 Jul; 37():100976. PubMed ID: 34386749
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibody persistence and safety and immunogenicity of a second booster dose nine years after a first booster vaccination with a reduced antigen diphtheria-tetanus-acellular pertussis vaccine (Tdap) in adults.
    Brandon D; Kimmel M; Kuriyakose SO; Kostanyan L; Mesaros N
    Vaccine; 2018 Oct; 36(42):6325-6333. PubMed ID: 30197282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety of Diphtheria and Tetanus Toxoids and Acellular Pertussis (DTaP) Vaccine in Adults in Japan.
    Ujiie M; Tsuzuki S; Suzuki M; Ota M; Suzuki T; Nomoto H; Yamamoto K; Saito S; Kokaze A; Kinoshita N
    Jpn J Infect Dis; 2021 Sep; 74(5):399-404. PubMed ID: 33518629
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized Controlled Trial of the Safety and Immunogenicity of Revaccination With Tetanus-Diphtheria-Acellular Pertussis Vaccine (Tdap) in Adults 10 Years After a Previous Dose.
    Halperin SA; Donovan C; Marshall GS; Pool V; Decker MD; Johnson DR; Greenberg DP;
    J Pediatric Infect Dis Soc; 2019 May; 8(2):105-114. PubMed ID: 29438562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.